Smart Nanosized Drug Delivery Systems Inducing Immunogenic Cell Death for Combination with Cancer Immunotherapy

doi:10.1021/acs.accounts.0c00254

	Smart Nanosized Drug Delivery Systems Inducing Immunogenic Cell Death for Combination with Cancer Immunotherapy
	Zhou, Lei 1,3,4; Zhang, Pengcheng 1,2,3; Wang, Hao 4; Wang, Dangge 1,2,3; Li, Yaping 1,2,3
刊名	ACCOUNTS OF CHEMICAL RESEARCH
	2020-09-15
卷号	53 期号:9 页码:1761-1772
ISSN号	0001-4842
DOI	10.1021/acs.accounts.0c00254
通讯作者	Wang, Dangge(dgwang@simm.ac.cn) ; Li, Yaping(ypli@simm.ac.cn)
英文摘要	CONSPECTUS: Cancer immunotherapy, which suppresses tumor relapse and metastasis by boosting host immunity and inducing long-term immune memory effects, is emerging as a vital approach to improve the prognosis of patients. Although remarkable efficacy has been observed in some patients, challenges including low response rate, drug resistance, and immune-related adverse effects still limit the clinical application of cancer immunotherapy in broad types of tumors. Immunotherapeutic agents are used to enhance tumor immunogenicity and reverse the effects of the immunosuppressive tumor microenvironment (ITM), but the benefits of monotherapy are mild and transient due to off-target distribution of drugs. To overcome these issues, smart nanosized drug delivery systems (sNDDS) have been developed to enhance tissue specificity, co-deliver multiple drugs, prime immune cells, and amplify immune responses in tumors. Moreover, accumulating knowledge in cancer biology, immunology, and material science has also greatly promoted the development of sNDDS for enhancing cancer immunotherapy. In this Account, we will discuss the approaches of our group in designing sNDDS to induce immunogenic cell death (ICD) for combination with cancer immunotherapy. We propose a brief overview on the design of nanocarriers, intelligent moieties and immunotherapeutic agents in sNDDS. Then, we discuss the strategies to remodel ITM by leveraging ICD as well as cooperating with programmed cell death protein 1 ligand blockade and indoleamine 2,3-dioxygenase 1 inhibition. We have synthesized a series of stimuli-responsive polymers and prodrugs to fabricate sNDDS and have integrated multiple immunotherapeutic drugs into one platform for combinational immunotherapy. Last, we present an outlook on future design of sNDDS and possible directions for enhancing cancer immunotherapy. Building on the concept of enhancing tumor immunogenicity and reversing ITM, we hope this Account will contribute to the rational design of sNDDS for co-delivery of multiple drugs with amplified immunotherapeutic efficacy.
资助项目	National Natural Science Foundation of China[81690265] ; National Natural Science Foundation of China[81521005] ; National Natural Science Foundation of China[81903548] ; Strategic Priority Research Program of CAS[XDA12050307] ; Youth Innovation Promotion Association of CAS[2019283] ; Shanghai Sailing Program[19YF1457300]
WOS关键词	IMMUNE CHECKPOINT BLOCKADE ; NANOPARTICLES ; THERAPY
WOS研究方向	Chemistry
语种	英语
出版者	AMER CHEMICAL SOC
WOS记录号	WOS:000572833000006
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/291286]
专题	中国科学院上海药物研究所
通讯作者	Wang, Dangge; Li, Yaping
作者单位	1.Chinese Acad Sci, State Key Lab Drug Res, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China 2.Yantai Inst Mat Med, Yantai Key Lab Nanomed & Adv Preparat, Yantai 264000, Shandong, Peoples R China 3.Chinese Acad Sci, Ctr Pharmaceut, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China 4.China State Inst Pharmaceut Ind, Shanghai 201203, Peoples R China
推荐引用方式 GB/T 7714	Zhou, Lei,Zhang, Pengcheng,Wang, Hao,et al. Smart Nanosized Drug Delivery Systems Inducing Immunogenic Cell Death for Combination with Cancer Immunotherapy[J]. ACCOUNTS OF CHEMICAL RESEARCH,2020,53(9):1761-1772.
APA	Zhou, Lei,Zhang, Pengcheng,Wang, Hao,Wang, Dangge,&Li, Yaping.(2020).Smart Nanosized Drug Delivery Systems Inducing Immunogenic Cell Death for Combination with Cancer Immunotherapy.ACCOUNTS OF CHEMICAL RESEARCH,53(9),1761-1772.
MLA	Zhou, Lei,et al."Smart Nanosized Drug Delivery Systems Inducing Immunogenic Cell Death for Combination with Cancer Immunotherapy".ACCOUNTS OF CHEMICAL RESEARCH 53.9(2020):1761-1772.